Understanding Implications of Proposed Best Price Revisions for Manufacturer Assistance Programs

Welcome to the latest eBook from MM+M...

On June 17, 2020, the Centers for Medicare and Medicaid Services issued a proposed rule that, if finalized, would revise how manufacturer coupons are accounted for in best price calculations. As a copay program provider, TrialCard believes this will have a negative effect on a pharmaceutical manufacturer’s ability to deliver much-needed patient assistance for high-cost specialty medications, many of which do not have generic alternatives. Access this important eBook today for more insights.

An in-depth discussion with Rick Fry, SVP, commercial solutions, TrialCard; Peter Pitts, president and cofounder, Center for Medicine in the Public Interest; Bill Sarraille, partner, Sidley Austin; Carl Schmid, executive director, HIV + Hepatitis Policy Institute; Stacey Worthy, partner, DBCA Law and executive director, Aimed Alliance; and Jason Zemcik, senior director, product management, TrialCard addressed how brands and pharmaceutical manufacturers can navigate the challenges of the proposed rule.

• Reducing the benefit amount of your copay offer to avoid being negatively exposed to best price reporting
• 
  
• Educating employer groups on the impact of copay accumulators beyond just financial savings tools including analyzing their effects on employee productivity and long-term healthcare costs
• 
  
• Designing healthcare programs to best address all of the complex issues of the proposed rule
• 
  
• Proactive steps that can be taken to mitigate potential effects of the proposed rule including working at the state level to combat it